WO2001004354A3 - Use of ras inhibitors of inhibiting muscle atrophy - Google Patents

Use of ras inhibitors of inhibiting muscle atrophy Download PDF

Info

Publication number
WO2001004354A3
WO2001004354A3 PCT/US2000/017173 US0017173W WO0104354A3 WO 2001004354 A3 WO2001004354 A3 WO 2001004354A3 US 0017173 W US0017173 W US 0017173W WO 0104354 A3 WO0104354 A3 WO 0104354A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscle atrophy
inhibiting
ras inhibitors
inhibiting muscle
provides
Prior art date
Application number
PCT/US2000/017173
Other languages
French (fr)
Other versions
WO2001004354A2 (en
Inventor
David J Glass
Christian Rommel
George D Yancopoulos
Original Assignee
Regeneron Pharma
David J Glass
Christian Rommel
George D Yancopoulos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, David J Glass, Christian Rommel, George D Yancopoulos filed Critical Regeneron Pharma
Priority to AU56323/00A priority Critical patent/AU5632300A/en
Priority to JP2001509553A priority patent/JP2003504351A/en
Priority to CA002378982A priority patent/CA2378982A1/en
Priority to EP00941641A priority patent/EP1192281A2/en
Publication of WO2001004354A2 publication Critical patent/WO2001004354A2/en
Publication of WO2001004354A3 publication Critical patent/WO2001004354A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides a method for inhibiting atrophy in muscle cells. It further provides a method for inhibiting skeletal muscle atrophy or causing skeletal muscle hypertrophy in vertebrate animals. It also provides a method of identifying agents, genes and gene products that may be used to reduce proteolysis or increase protein synthesis in muscle cells.
PCT/US2000/017173 1999-07-07 2000-06-22 Use of ras inhibitors of inhibiting muscle atrophy WO2001004354A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU56323/00A AU5632300A (en) 1999-07-07 2000-06-22 Methods of inhibiting muscle atrophy
JP2001509553A JP2003504351A (en) 1999-07-07 2000-06-22 How to inhibit muscle atrophy
CA002378982A CA2378982A1 (en) 1999-07-07 2000-06-22 Methods of inhibiting muscle atrophy
EP00941641A EP1192281A2 (en) 1999-07-07 2000-06-22 Use of ras inhibitors for inhibiting muscle atrophy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14285799P 1999-07-07 1999-07-07
US60/142,857 1999-07-07

Publications (2)

Publication Number Publication Date
WO2001004354A2 WO2001004354A2 (en) 2001-01-18
WO2001004354A3 true WO2001004354A3 (en) 2001-08-16

Family

ID=22501570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/017173 WO2001004354A2 (en) 1999-07-07 2000-06-22 Use of ras inhibitors of inhibiting muscle atrophy

Country Status (5)

Country Link
EP (1) EP1192281A2 (en)
JP (1) JP2003504351A (en)
AU (1) AU5632300A (en)
CA (1) CA2378982A1 (en)
WO (1) WO2001004354A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085364A1 (en) * 2001-04-25 2002-10-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating cachexia
EP3070174B1 (en) 2004-05-11 2019-11-06 Ncardia AG Drug discovery based on in vitro differentiated cells
EP2321346A1 (en) * 2008-08-13 2011-05-18 University of Szeged Methods and substances for stimulating muscle regeneration
AU2011345312A1 (en) * 2010-11-09 2013-06-20 Sarcotein Diagnostics Llc BIN1 expression as a marker of skeletal muscle mass and neurological conditions
JP6170925B2 (en) 2011-09-30 2017-07-26 サーコーティン ダイアグノスティックス エルエルシー Expression of BIN1 as a marker for cancer
WO2015085097A1 (en) 2013-12-05 2015-06-11 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
WO2016141088A1 (en) 2015-03-02 2016-09-09 Sarcotein Diagnostics, Llc 13+/17+ bin1 expression as a marker of cardiac disorders
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOWEN D C ET AL: "Regulation of MuSK expression in skeletal muscle during development and after injury.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 22, no. 1-3, 1996, 26th Annual Meeting of the Society for Neuroscience;Washington, D.C., USA; November 16-21, 1996, pages 1476, XP000986706, ISSN: 0190-5295 *
COLEMAN M E ET AL: "MYOGENIC VECTOR EXPRESSION OF INSULIN-LIKE GROWTH FACTOR I SIMULATES MUSCLE CELL DIFFERENTIATION AND MYOFIBER HYPERTROPHY IN TRANSGENIC MICE", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12109 - 12116, XP000611917, ISSN: 0021-9258 *
COOLICAN SHARON A ET AL: "The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 10, 1997, pages 6653 - 6662, XP002161387, ISSN: 0021-9258 *
DUDLEY DAVID T ET AL: "A synthetic inhibitor of the mitogen-activated protein kinase cascade.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 17, 1995, 1995, pages 7686 - 7689, XP002161388, ISSN: 0027-8424 *
ROMMEL CHRISTIAN ET AL: "Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.", SCIENCE (WASHINGTON D C), vol. 286, no. 5445, 26 November 1999 (1999-11-26), pages 1738 - 1741, XP002161386, ISSN: 0036-8075 *
SAMUEL D S ET AL: "Raf-1 activation stimulates proliferation and inhibits IGF-stimulated differentiation in L6A1 myoblasts.", HORMONE AND METABOLIC RESEARCH, vol. 31, no. 2-3, February 1999 (1999-02-01), pages 55 - 64, XP000986726, ISSN: 0018-5043 *

Also Published As

Publication number Publication date
AU5632300A (en) 2001-01-30
JP2003504351A (en) 2003-02-04
CA2378982A1 (en) 2001-01-18
EP1192281A2 (en) 2002-04-03
WO2001004354A2 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
EP1246621A4 (en) Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
WO2003093441A3 (en) A method of regulating gene expression
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AU2003265859A1 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
AU2003258196A1 (en) Process for the selection and evaluation of investment portfolio asset allocation strategies
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
ZA200208262B (en) Inhibition of biological degradation in Fischer-Tropsch products.
AU2002301456A1 (en) Inhibition of biological degradation in Fischer-Tropsch products
WO2004064832A3 (en) Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy
NO20000475L (en) Corrosion inhibitor compositions, methods of use, and processes for their preparation
AU2002255756A1 (en) System for screening fatty acid transport inhibitors, methods of use and modulators identified thereby
WO2002069890A3 (en) Methods of identifying agents affecting atrophy and hypertrophy
WO2004052919A3 (en) Peptide deformylase inhibitors
WO2003087051A3 (en) Methods for identifying allosteric sites
AU2003294291A1 (en) Descaling and corrosion inhibiting composition
EP1012313A4 (en) INTRACELLULAR INHIBITORS OF Gq PROTEIN SIGNALING
AU2002252950A1 (en) Protein kinase d inhibitors and protein kinase 2 inhibitors as agents for inhibiting tumour cells and for stimulating angiogenesis
WO2002070540A3 (en) Peptide deformylase inhibitors
WO2005032550A3 (en) Peptide deformylase inhibitors
AU2003268340A1 (en) Methods and compositions for the inhibition of dna repair protein xrcc-3
AU2003235787A1 (en) Method for carrying out the product-accompanying or manufacturing-accompanying documentation and/or characterization of transportable objects as well as the subsequent identification thereof
AU2003217392A1 (en) Methods for identifying targeting domains and methods and compositions comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 509553

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2378982

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000941641

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000941641

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10018761

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000941641

Country of ref document: EP